Superoxide dismutase - Weizmann Institute

Drug Profile

Superoxide dismutase - Weizmann Institute

Alternative Names: OxSODrol; rhSOD1

Latest Information Update: 09 Oct 2007

Price : $50

At a glance

  • Originator Weizmann Institute of Science
  • Developer JCR Pharmaceuticals
  • Class Anti-inflammatories; Anti-ischaemics; Antirheumatics; Oxidoreductases
  • Mechanism of Action Superoxide dismutase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Amyotrophic lateral sclerosis; Asthma; Ischaemic heart disorders; Neonatal respiratory distress syndrome; Respiratory syncytial virus infections

Most Recent Events

  • 05 Dec 2003 No development reported - Clinical-Phase-Unknown for Asthma prevention in USA (Intratracheal)
  • 05 Dec 2003 No development reported - Phase-I for Amyotrophic lateral sclerosis in USA (Intrathecal)
  • 05 Dec 2003 No development reported - Phase-I for Ischaemic heart disorders in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top